Biobanking in LMIC settings for infectious diseases: Challenges and enablers  

作　　者：Sameera Ezzat Ruzica Biga Zisis Kozlakidis 

机构地区：[1]National Liver Institute,Menoufia University,Shibin el Kom 32511,Egypt [2]Mounir Armanious Research Center(MARC),Giza 12561,Egypt [3]University Cote D’Azur,Nice 06103,France [4]International Agency for Research on Cancer,World Health Organization,Lyon 69372,France

出　　处：《Biosafety and Health》2022年第5期290-292,共3页生物安全与健康（英文）

摘　　要：Biobanking facilities are well established in high-income settings,where substantial funding has been invested in infrastructure.In contrast,such facilities are much less developed in resource-restricted settings.However,low-and middle-income countries(LMICs)still face a disproportionately high infectious diseases burden.Thus,the further development of infrastructure facilities,including biobanks is warranted as an important component of this unfolding clinical research environment.This perspective manuscript summarises the challenges and enablers for biobanking in LMICs,with a particular focus on infectious diseases,incorporating some of the lessons learned from the recent coronavirus disease 2019(COVID-19)pandemic.

关 键 词：BIOBANKING Research infrastructures Infectious diseases Low-and-middle income countries LMICs 

分 类 号：R181[医药卫生—流行病学]